Introduction: The role of adjuvant chemotherapy for patients with stage I NSCLC remains unknown. The prognostic value of histological subtypes in resected node-negative small lung adenocarcinoma has not been widely investigated. This study investigated the prognostic factors in patients with node-negative lung adenocarcinoma 3 cm or smaller to find potential candidates for adjuvant chemotherapy.
Methods: A total of 726 patients with completely resected node-negative lung adenocarcinoma 3 cm or smaller were included in the study. Prognostic factors for overall survival or probability of freedom from recurrence (FFR) were investigated.
Results: During follow-up, recurrence developed in 59 patients (8.1% ). Univariate analysis showed that the micropapillary/solid predominant pattern group was associated with a significantly lower probability of FFR (p ¼ 0.001) in node-negative lung adenocarcinoma 3 cm or smaller. Those with greater tumor size (p ¼ 0.001) and the micropapillary/solid predominant pattern group (p ¼ 0.035) had a significantly lower probability of FFR in multivariate analysis. For tumors 2 cm or smaller, the micropapillary/ solid predominant pattern group had a trend toward a lower probability of FFR (p ¼ 0.053) in multivariate analysis. Presence of the solid pattern was a prognostic factor for lower probability of FFR (p ¼ 0.001) in multivariate analysis.
Conclusions:
The new adenocarcinoma classification has significant impact on recurrence in node-negative lung adenocarcinoma 3 cm or smaller. Patients with the micropapillary/solid predominant pattern have a significantly higher risk for recurrence. For tumors 2 cm or smaller, presence of the solid pattern was a prognostic factor for higher probability of recurrence. This information is useful for patient stratification for adjuvant therapy.
Introduction
Lung cancer is the leading cause of cancer death worldwide. 1 Surgical resection is the treatment of choice for early-stage NSCLC. 2, 3 The 5-year survival rates of patients with resected pathologic stage IA and IB NSCLC were 83% and 71%, respectively. 3 Even in stage IA or node-negative lung cancer 3 cm or smaller, tumor recurrence is the major cause of treatment failure after resection. [4] [5] [6] Therefore, the identification of prognostic factors for death or recurrence in stage IA or small node-negative lung cancer will aid in stratifying high-risk patients for further design of clinical trials to demonstrate the benefits of adjuvant chemotherapy.
In 2011, the International Association for the Study of Lung Cancer, the American Thoracic Society, and the European Respiratory Society proposed a new classification system for lung adenocarcinoma. 7 Several studies have reported on the impact of the new classification on death, recurrence, and postrecurrence survival. [8] [9] [10] [11] [12] [13] [14] In our previous reports, 15, 16 we have shown that the micropapillary and solid predominant subtypes were significant prognostic factors for death and recurrence. 15, 16 We have also shown that patients having stage IB lung adenocarcinoma with the micropapillary/ solid predominant pattern had a significantly improved probability of freedom from recurrence (FFR) when they received platinum-based adjuvant chemotherapy. 17 However, the prognostic value of the new classification in stage IA or node-negative lung adenocarcinoma 3 cm or smaller has not been well demonstrated. [4] [5] [6] Therefore, the present study aimed to investigate the prognostic value of the new classification in completely resected node-negative lung adenocarcinoma 3 cm or smaller.
Patients and Methods

Patients
This study was approved by the Institutional Review Board of Taipei Veterans General Hospital. From January 2004 to December 2014, all patients who underwent a completely resection for lung adenocarcinomas at Taipei Veterans General Hospital were retrospectively reviewed. Patients undergoing neoadjuvant chemotherapy or radiotherapy were excluded. Patients with adenocarcinoma in situ or minimally invasive adenocarcinoma were also excluded. A total of 746 patients who had undergone resection for pathological node-negative lung adenocarcinomas 3 cm or smaller were identified. Among them, 20 patients with unknown recurrence status during followup were excluded from analysis. The remaining 726 patients were enrolled in the study. The preoperative staging work-up, including chest and upper abdomen computed tomography (CT), brain CT scan or magnetic resonance imaging, and a nuclear medicine survey of the bone, was performed as previously described. 15, 16 Positron emission tomography/CT scans were available as a staging modality in 328 of the 726 patients (45.2%). Mediastinoscopy or endobronchial ultrasound was performed when enlarged mediastinal lymph nodes (diameter >1.0 cm) were shown by CT scan or when increased uptake at mediastinal lymph nodes was shown by positron emission tomography/CT scan. All the patients underwent complete resection of their lung cancer with mediastinal lymph node dissection as previously described. 15, 16 Lobectomy was the standard procedure. For ground glass nodules 2 cm or smaller and with a distance to the chest wall 2 cm or less, sublobar resection may be considered according to surgeon preference. For patients older than 80 years with poor pulmonary function or comorbidities, sublobar resection may also be considered. No pleural lavage was performed during the operation.
Clinicopathological Characteristics
To investigate their prognostic value, clinicopathologic factors were examined in univariate and multivariate analyses. All resected specimens were fixed in formalin, stained with hematoxylin and eosin, and evaluated microscopically by two pathologists as described previously. 16 If there were discrepancies in results, the two pathologists discussed them to reach agreement. The pathologists were blinded to the patients' outcomes. The criteria of the new International Association for the Study of Lung Cancer/American Thoracic Society/ European Respiratory Society classification of lung adenocarcinoma were used for histological classification. 7, 18 Each tumor was reviewed by using comprehensive histological subtyping and recording the percentage of each histological component (lepidic, acinar, papillary, micropapillary, and solid) in 5% increments. 7 The predominant pattern was defined according to the most dominant pattern. Presence of a specific histological pattern was defined as percentage of the specific histological component of at least 5%. Determination of visceral pleural invasion (VPI) was done as previously described. 19, 20 VPI was classified as follows: PL0, tumor within the subpleural lung parenchyma or invading superficially into the pleural connective tissue beneath the elastic layer; PL1, invasion beyond the elastic layer; and PL2, invasion to the surface of the visceral pleura. VPI was first examined in tumor sections with hematoxylin and eosin stain. Elastic stains were performed in tumor sections when the status of VPI was indeterminate by hematoxylin and eosin stains. PL1 and PL2 indicated VPI. Determination of disease stages was based on the TNM classification (seventh edition) of the American Joint Committee on Cancer. 21 Although the use of adjuvant chemotherapy was not randomized but took place according to physician preference in the current study, patients with a predominantly micropapillary/solid pattern were more likely to be offered adjuvant chemotherapy (p < 0.001).
Patient Follow-up
All patients were followed up at our outpatient department every 3 months in the first 2 years after resection and at 6-month intervals thereafter as previously described. 15, 16 The modalities and protocols used during follow-up were as previously described. 13, 15, 16 CT scans of the chest and upper abdomen were the routine examinations performed in every outpatient department visit for follow-up. Nuclear medicine survey of the bone was arranged every 6 months in the first 2 years after resection and annually thereafter during follow-up. Suspicious bony lesions were confirmed by radiography or bone biopsy. Brain CT scan or magnetic resonance imaging was done when neurological symptoms occurred or when clinical suspicions were raised. Once a metastasis was discovered, a routine investigation was arranged to look for other metastatic sites. After initial diagnosis of recurrence, further examinations were arranged to discover other metastatic sites if symptoms occurred or clinical suspicions were raised. Secondary primary lung cancer was differentiated from recurrent NSCLC according to the suggestions by Detterbeck et al. 22, 23 The duration of overall survival was defined as the interval between the date of surgical resection and the date of either death or the last follow-up. The period of FFR was defined as the interval between the date of surgical resection and the date of recurrence or the last follow-up. The date of recurrence was the date on which tissue confirmation for recurrence was made. For those not undergoing resection or biopsy, judgment was made according to clinical course and the date of recurrence was the date on which the judgment was made. An observation was censored at the last follow-up session when the patient was alive with recurrence-free status or had died without recurrence.
Statistical Analysis
The overall survival and probability of FFR were calculated by the Kaplan-Meier method. 24 The log-rank test was used to make group comparisons. Univariate and multivariate analyses were performed by means of the Cox proportional hazards model using SPSS Statistics (version 20 [IBM Corp., Armonk, NY]). All variables with p less than 0.1 in univariate analysis were entered into the multivariate analysis. Statistical significance was defined as p less than 0.05.
Results
The median follow-up time for all 726 patients was 28.3 months (range 0.7-113.1 months). The characteristics of all the patients are listed in Table 1 . For all patients, the 5-year overall survival and probability of FFR were 90.2% and 84.8%, respectively (Figs. 1A and B). Two postoperative deaths (0.3%) occurred (lobectomy had been performed in one patient and wedge resection in the other patient). Of the 726 patients, 183 patients (25.2%) underwent wedge resection, 19 (2.6%) underwent segmentectomy, 522 (71.9%) underwent lobectomy, and two (0.3%) underwent bilobectomy. Of the 726 patients, 495 (68.2%) presented with the lepidic pattern, 629 (86.6%) with the acinar pattern, 357 (49.2%) with the papillary pattern, 150 (20.7%) with the micropapillary pattern, and 125 (17.2%) with the solid pattern (see Table 1 ). With regard to predominant pattern, there were 188 patients (25.9%) with lepidic predominant, 303 (41.7%) with acinar predominant, 131 (18.0%) with papillary predominant, 64 (8.8%) with micropapillary predominant, and 40 (5.5%) with solid predominant adenocarcinomas. Of the 726 patients, 667 (91.9%) were free of tumor recurrence and 59 (8.1%) experienced recurrence during follow-up. The median time to recurrence for the 59 patients with recurrence was 17.9 months (range 1.7-87.2 months).
Overall Survival in Patients with Node-Negative Adenocarcinoma 3 cm or Smaller
The median age of all the patients was 63.0 years. Therefore, we used 63 years as the cutoff value for age. Univariate analysis indicated that age older than 63 years (p ¼ 0.004) and larger tumor size (p < 0.001) were significant prognostic factors for worse overall survival (Table 2 ). Female sex (p ¼ 0.027) and lobectomy or greater (p ¼ 0.006) were significant prognostic factors for better overall survival (see Table 2 ). The predominant pattern group (micropapillary/solid predominant versus lepidic/ acinar/papillary predominant) was not a significant prognostic factor for overall survival (p ¼ 0.146). In multivariate analysis, larger tumor size (hazard ratio [HR] ¼ 3.819, 95% confidence interval [CI]: 1.568-9.299, p ¼ 0.003) was a significant prognostic factor for worse overall survival, whereas lobectomy or greater (HR ¼ 0.184, 95% CI: 0.068-0.504, p ¼ 0.001) was a significant prognostic factor for better overall survival (see Table 2 ).
Probability of FFR in Patients with Node-Negative Adenocarcinoma 3 cm or Smaller
Univariate analysis indicated that age older than 63 years (p ¼ 0.006), larger tumor size (p < 0.001), VPI (p ¼ 0.002), predominant pattern group (micropapillary/solid predominant versus lepidic/acinar/ papillary predominant) (p ¼ 0.001) (Fig. 2A) , adjuvant chemotherapy (p ¼ 0.022), and comorbidity (p ¼ 0.031) were significant prognostic factors for lower probability of FFR (see Table 2 ). In multivariate analysis, larger tumor size (HR ¼ 2.199, 95% CI: 1.401-3.451, p ¼ 0.001) and predominant pattern group (micropapillary/solid predominant versus lepidic/acinar/papillary predominant) (HR ¼ 1.886, 95% CI: 1.046-3.399, p ¼ 0.035) were still significant prognostic factors for lower probability of FFR (see Table 2 ).
We further examined the cumulative predictive value on recurrence of these risk factors. The probability of FFR was significantly lower in patients with a tumor larger than 2 cm but no larger than 3 cm than in those patients with a tumor 2 cm or smaller (p ¼ 0.004). Tumor size larger than 2 cm but no larger than 3 cm and the micropapillary/solid predominant pattern were used as risk predictors for recurrence. All patients were divided into two groups according to number of positive risk predictors: no or one positive risk predictor (group 1) and two positive risk predictors (group 2). KaplanMeier analysis showed that patients with both positive risk predictors had a significantly higher probability of recurrence than others (p ¼ 0.006) (Fig. 2B ).
Probability of FFR in Patients with Node-Negative Adenocarcinoma 2 cm or Smaller
Among all the patients, 456 (62.8%) had lung adenocarcinoma 2 cm or smaller. We further examined the prognostic value of histological subtypes in these patients. Because only six deaths occurred in these patients, we examined only the prognostic factors of probability of FFR. The median age of all the 456 patients was 62.0 years. Therefore, we used 62 years old as the cutoff value of age. Univariate analysis indicated that age older than 62 years (p ¼ 0.043), greater smoking exposure (p ¼ 0.011), larger tumor size (p ¼ 0.002), predominant pattern group (micropapillary/solid predominant versus lepidic/acinar/ papillary predominant) (p ¼ 0.005), comorbidity (p ¼ 0.047), and adjuvant chemotherapy (p ¼ 0.036) were significant prognostic factors for lower probability of FFR in node-negative adenocarcinoma 2 cm or smaller (Table 3) . In multivariate analysis, larger tumor size (HR ¼ 5.819, 95% CI: 1.643-20.609, p ¼ 0.006) and greater smoking exposure (HR ¼ 1.020, 95% CI: 1.003-1.037, p ¼ 0.022) were still significant prognostic factors for lower probability of FFR (Table 4 ). The predominant pattern group (micropapillary/solid predominant versus lepidic/acinar/papillary predominant) (p ¼ 0.053) had a trend toward a lower probability of FFR.
Because the predominant pattern group (micropapillary/solid predominant versus lepidic/acinar/ papillary predominant) was not a significant prognostic factor of probability of FFR in multivariate analysis, we further examined the prognostic value of presence of each histological subtype. Univariate analysis indicated that presence of the solid pattern (p < 0.001) was a significant prognostic factor for lower probability of FFR (see Table 3 and Fig. 2C) . Presence of the lepidic pattern (p ¼ 0.056) showed a trend toward a higher probability of FFR, whereas presence of the micropapillary pattern (p ¼ 0.097) showed a trend toward a lower probability of FFR. In the model with the histological pattern entered as present versus absent in multivariate analysis, larger tumor size (HR ¼ 5.394, Table 4 ). We further examined the cumulative predictive value of these risk factors in relation to recurrence. The probability of FFR was significantly lower in patients with a tumor larger than 1 cm but no larger than 2 cm than in those patients with a tumor 1 cm or smaller (p ¼ 0.005). Tumor larger than 1 cm but no larger than 2 cm and presence of the solid pattern were used as risk predictors for recurrence. All patients were divided into two groups according to number of positive risk predictors: no or one positive risk predictor (group 1) and two positive risk predictors (group 2). Kaplan-Meier analysis showed that patients with both positive risk predictors had a significantly higher probability of recurrence than others (p < 0.001) (Fig. 2D) .
Discussion
This study investigated the prognostic factors of overall survival and probability of FFR in patients with completely resected node-negative lung adenocarcinoma 3 cm or smaller. The micropapillary/solid predominant pattern was a significant prognostic factor for lower probability of FFR. For tumors 2 cm or smaller, presence of the solid pattern was a significant prognostic factor for lower probability of FFR. Although the prognostic value of the new classification on survival and recurrence has been reported in the literature, [8] [9] [10] [11] [12] [13] only a few reports have demonstrated its prognostic value in stage IA or node-negative lung adenocarcinoma 3 cm or smaller. Zhang et al. 4 reported that the solid predominant with mucin production and micropapillary predominant subtypes were associated with poor prognosis in a cohort of 176 patients with pathological stage IA lung adenocarcinoma. Sasada et al. 5 reported that malignant potential was higher for pure than for partially invasive lung adenocarcinomas in a cohort of 167 patients with invasive stage IA lung adenocarcinoma. They also found that the papillary and acinar predominant subtypes were more common in partially invasive tumors, whereas the solid and micropapillary predominant subtypes were more common in pure invasive tumors. Yoshiya et al. 6 reported that the micropapillary or solid predominant subtype was a poor prognostic factor in a cohort of 153 patients with small (2 cm) pathological N0 lung adenocarcinoma. The current study is, to the best of our knowledge, the largest analyzing the prognostic value of the histological subtypes in small (3 cm) node-negative lung adenocarcinomas. Our results showed that the micropapillary/solid predominant pattern was a significant prognostic factor for lower probability of FFR in a cohort of 726 patients with node-negative lung adenocarcinoma 3 cm or smaller. For tumors 2 cm or smaller, the micropapillary/ solid predominant pattern had a trend toward a lower probability of FFR. We further showed that presence of the solid pattern was a significant prognostic factor for lower probability of FFR.
The predictive value of histological subtypes in lung adenocarcinoma has not been well demonstrated in the literature. [25] [26] [27] In a LACE-BIO study-related report, patients with micropapillary/solid predominant (but not acinar/papillary) adenocarcinomas obtained a diseasefree survival and specific disease-free survival but no overall survival benefit from adjuvant chemotherapy. 25, 26 Leeman et al. 28 reported that the outcomes after stereotactic body radiation therapy for early-stage (I-IIA) lung adenocarcinoma correlate highly with histological subtype, with micropapillary and solid tumors portending significantly higher rates of locoregional and metastatic progression. Whether adjuvant chemotherapy improves survival in patients with stage I lung cancer remains controversial. [29] [30] [31] In our previous study 17 regarding the effect of adjuvant chemotherapy in stage IB lung adenocarcinoma, adjuvant chemotherapy was a significant prognostic factor for higher probability of FFR. We have also shown that patients having stage IB lung adenocarcinoma with the micropapillary/solid predominant pattern had a significantly improved probability of FFR when they received platinum-based adjuvant chemotherapy. 17 The effect of adjuvant chemotherapy in stage IA or node-negative lung adenocarcinoma 3 cm or smaller is unknown and needs investigation. Identification of prognostic factors in these small node-negative lung adenocarcinomas is helpful to stratify patients with a high risk for death or recurrence for future design of clinical trials. The current study showed that patients with small (3 cm) node-negative micropapillary/solid predominant lung adenocarcinoma had a higher risk for recurrence after surgical resection. Therefore, the micropapillary/solid predominant pattern may be proposed as a stratification factor in the design of future multi-institutional studies or randomized clinical trials to demonstrate the effect of adjuvant chemotherapy in patients with node-negative lung adenocarcinoma 3 cm or smaller. Presence of the solid pattern may be proposed as a stratification factor in the design of randomized clinical trials to investigate the role of adjuvant chemotherapy in patients with nodenegative lung adenocarcinoma 2 cm or smaller.
The prognostic value of several conventional clinicopathological variables in stage IA lung cancer has been reported in the literature. 4, 6, 32, 33 Zhang et al. 4 reported that male sex was a significant prognostic factor for poor disease-free survival in patients with pathological stage IA lung adenocarcinoma. In the report by Yoshiya et al. 6 regarding prognosis in patients with small ( 2 cm) pathological N0 lung adenocarcinoma, no significant prognostic factor for recurrence-free survival other than micropapillary or solid predominant subtype was identified. Takenaka et al. 32 reported that volume of the solid part of the tumor was an independent factor for the prediction of disease-free survival in patients with stage IA NSCLC. Zhong et al. 33 reported that tumor size was an independent prognostic factor for poor disease-free survival in patients with small (2 cm) stage IA NSCLC. In our study, larger tumor size and the predominant pattern group (micropapillary/solid predominant) were significant prognostic factors for lower probability of FFR. We further proposed a model in which patients with both positive risk predictors (tumor >2 cm but 3 cm and micropapillary/solid predominant pattern) had a significantly higher probability of recurrence than others. For tumors 2 cm or smaller, larger tumor size and presence of the solid pattern were significant prognostic factors for lower probability of FFR. Patients with both positive risk predictors (tumor larger than 1 cm but no larger than 2 cm and presence of the solid pattern) had significantly a higher probability of recurrence than others. These models help to identify patients with higher risk for recurrence for possible further adjuvant therapy.
Some limitations of this study should be mentioned. In a retrospective study, patient selection bias and time trend bias are inevitable. Another limitation is that the use of adjuvant chemotherapy in the cohort was according to physicians' preference. To evaluate the benefit of adjuvant chemotherapy for small early-stage lung cancer, the number of patients was too small. Prospective multi-institutional studies and randomized clinical trials are mandatory to validate further the prognostic and predictive value of histological subtypes for benefits from adjuvant chemotherapy.
In conclusion, the histological subtypes of lung adenocarcinoma have significant impact on recurrence in node-negative lung adenocarcinomas 3 cm or smaller. The micropapillary/solid predominant pattern is a significant risk factor for recurrence. For tumors 2 cm or smaller, presence of the solid pattern is a significant prognostic factor for higher probability of recurrence. This information is useful for patient stratification for future design of clinical trials for aggressive adjuvant therapy.
